Various tests for specific biomarkers, including prostate-specific antigen (PSA), Kallikrein 2 (hK2), urokinase plasminogen activator (uPA), transforming growth factor-beta 1 (TGF-Beta 1), interleukin-6 (IL-6), VEGF, prostate cancer antigen (PCA), CCL11/Eotaxin chemokine, and also microRNA (miRNA) are performed in the diagnosis of prostate diseases in men as an addition to the standard clinical examination. This evidence concerns the gene IL6 and prostatitis.